Neurologic soft signs and olanzapine treatment in chronic schizophrenia.
Sevincok
Levent
L
Topaloglu
Beyza
B
Kiyilioglu
Nefati
N
D000328:Adult; D017109:Akathisia, Drug-Induced / Q000175:diagnosis*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000175:diagnosis; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009460:Neurologic Examination / Q000187:drug effects*; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis* / Q000188:drug therapy*; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine